Press release
Revance Therapeutics, Inc. (NASDAQ: RVNC) Investor Alert: Deadline in Lawsuit on March 4, 2025
A Deadline is coming up on March 4, 2025 in the lawsuit for certain investors in Revance Therapeutics, Inc. (NASDAQ: RVNC).
Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and there are strict and short deadlines running. Deadline: March 4, 2025. Revance Therapeutics, Inc. (NASDAQ: RVNC) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Middle District of Tennessee the plaintiff alleges on behalf of purchasers of Revance Therapeutics, Inc. (NASDAQ: RVNC) common shares between February 29, 2024 and December 6, 2024, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 29, 2024 and December 6, 2024, the Defendants made false and/or misleading statements and/or failed to disclose that Revance was in material breach of the Distribution Agreement, thst the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm, that all the foregoing increased the risk that the Tender Offer would be delayed and/or amended, and that as a result, the Company's public statements were materially false and misleading at all relevant times
Those who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Revance Therapeutics, Inc. (NASDAQ: RVNC) Investor Alert: Deadline in Lawsuit on March 4, 2025 here
News-ID: 3888992 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for investors who lost money with shares of iRobot Corporation (NA …
An investor, who purchased shares of iRobot Corporation (NASDAQ: IRBT), filed a lawsuit over alleged violations of Federal Securities Laws by iRobot Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of iRobot Corporation (NASDAQ: IRBT) have certain options and for certain investors are short and strict deadlines running. Deadline: September 5, 2025. NASDAQ: IRBT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Long-Term Investors in shares of Ibotta, Inc. (NYSE: IBTA) should contact the Sh …
An investigation was announced for current long-term investors in shares of Ibotta, Inc. (NYSE: IBTA) concerning potential breaches of fiduciary duties by certain directors and officers of Ibotta, Inc.
Investors who are current long term investors in Ibotta, Inc. (NYSE: IBTA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Organon & Co. (NYSE: OGN) Investor Alert: Deadline in Lawsuit on July 22, 2025
A deadline is coming up on July 22, 2025 in the lawsuit filed for certain investors of Organon & Co. (NYSE: OGN) over alleged securities laws violations by Organon & Co.
Investors who purchased shares of Organon & Co. (NYSE: OGN) have certain options and there are strict and short deadlines running. Deadline: July 22, 2025. NYSE: OGN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of NET Power Inc. (NYS …
An investigation on behalf of current long-term investors in shares of NET Power Inc. (NYSE: NPWR) concerning potential breaches of fiduciary duties by certain directors and officers of NET Power Inc. was announced.
Investors who are current long term investors in NET Power Inc. (NYSE: NPWR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for…
More Releases for Revance
Aesthetic Service Market Is Booming Worldwide | Allergan, Galderma, Merz Pharmac …
The Global Aesthetic Service Market is estimated to be valued at USD 21.94 Bn in 2025 and is expected to reach USD 36.40 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.5% from 2025 to 2032.
The qualitative latest Research report (2025-2032) on the Aesthetic Service Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes…
Lip Augmentation Market Trends and Forecast | Key Players: Revance Therapeutics, …
Lip Augmentation Market Overview
The global lip augmentation market is projected to grow from USD 3.1 billion in 2024 to USD 6.1 billion by 2033, exhibiting a CAGR of 7.78% during the forecast period.
Coherent Market Insights is pleased to release its latest Lip Augmentation Market research report, offering an in-depth analysis of the U.S. Lip Augmentation Market Landscape from 2025 to 2032. This report delivers reliable projections across national and regional…
Medical Aesthetics Market Thrives Amid Rising Cosmetic Procedures Demand | Aller …
Medical Aesthetics Market Overview
Medical Aesthetics Market is projected to grow from USD 14.23 billion in 2023 to USD 34.68 billion by 2032, registering a CAGR of 10.5% during the forecast period.
The latest report (2025-2032) on the Medical Aesthetics Market by Coherent Market Insights offers an in-depth analysis of market trends, growth factors, challenges, and competition. It explores market size, revenue, production, consumption, and CAGR, using reliable research methods for accuracy.…
Facial Injectable Market Is Booming So Rapidly | Evolus, Hugel, Revance
The Global Facial Injectable Market Size is estimated at $12.9 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 10.1% to reach $30.7 Billion by 2034.
The latest study released on the Global Facial Injectable Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Facial Injectable market study covers significant research data and proofs to be a handy resource document for…
Investigation announced for Investors in Revance Therapeutics, Inc. (NASDAQ: RVN …
An investigation was announced for long-term investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) concerning potential breaches of fiduciary duties by certain directors and officers of Revance Therapeutics, Inc.
Investors who are current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVN …
An investor in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) filed a lawsuit over alleged Securities Laws violations by Revance Therapeutics, Inc.
Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and for certain investors are short and strict deadlines running. Deadline: February 8, 2022. NASDAQ: RVNC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Newark, CA based Revance Therapeutics, Inc.,…
